Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580336 | 0.95 | ATM (0.52) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL1578993 | 0.93 | ATM (0.47) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL7514173 | 0.91 | ATM (0.45) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL1579968 | 0.88 | ATM (0.45) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL1578576 | 0.88 | ATM (0.48) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL4417462 | 0.84 | ATM (0.71) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8552859 | 0.83 | L3MBTL1 (0.71) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL21568846 | 0.82 | ATM (0.68) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL4417681 | 0.82 | ATM (0.68) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8557820 | 0.81 | L3MBTL1 (0.62) | ATML3MBTL1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | claimed |
| JP-2011526616-A | — | — | 2011-10-13 | — | — | JP | claimed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | claimed |
| EP-2310010-A2 | CHEMICAL COMPOUNDS 251 | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | claimed |
| WO-2010001169-A2 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | WO | claimed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | ATM 710/4885L3MBTL1 1902/4885MEN1 3123/4885 |
| US-20150051185-A1 | Chemical Compounds 251 | PIM1, PIM3, PIM2 | ATM 649/4885L3MBTL1 2095/4885MEN1 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.